TB-500 and thymosin beta-4: the fragment versus the protein posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
No notes. Posting so the count is not one.
Narrowing post #31, because the general version has more than one answer.
TB-500 is a fragment rather than the whole thymosin beta-4 protein, and the two are used interchangeably in product descriptions when they should not be. The fragment is what is generally supplied.
Somebody will have a better source than mine, and I hope they post it.
I have no financial interest in anything named in this thread and I want to say so before I comment on TB-500 and thymosin beta-4, because it is the sort of subject where it matters.
Practical answer on TB-500 and thymosin beta-4, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Not the answer, but possibly the question that gets there.
Answering the question post #34 raises rather than the one it answers.
Route arguments — local versus systemic — are made confidently in this subcategory on very little published basis. The honest position is that the comparison has not been studied in humans.
I have kept the units in throughout, for the obvious reason.
Post #36 is the version of this I will quote in future. One addition.
The failure mode on TB-500 and thymosin beta-4 is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
Where I part company with post #38, and it is a narrow parting.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
I would call the community position on TB-500 and thymosin beta-4 likely rather than established, and I would be comfortable defending that hedge.
I read post #39 twice before replying, because I had assumed the opposite.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
It is a small point and it changes the answer, which is an awkward combination.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
Picking up post #43: that is the part I would want checked first.
What I can speak to on TB-500 and thymosin beta-4 is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Collapsed as off-topic by two members at trust level 3 or above
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
One more thing on TB-500 and thymosin beta-4 that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Post #48 put the caveat in the right place and I want to underline it.
Reporting rather than recommending, on TB-500 and thymosin beta-4. What happened is above. Whether it should have is a different question and not one I am qualified to answer.
Building on post #48 rather than restating it.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
Reading it again, the caveat matters more than the finding.
Adding the measurement that post #50 says would settle it.
I would be cautious about generalising from the TB-500 and thymosin beta-4 example above. It is a good example. It is one example.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Picking up post #54: that is the part I would want checked first.
TB-500 and thymosin beta-4 was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Two sources, same conclusion, and I could not rule out that one copied the other.
Collapsed as off-topic by two members at trust level 3 or above
Reading this TB-500 and thymosin beta-4 thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
The version of TB-500 and thymosin beta-4 that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.